Ultimovacs ASA (Norway) Analysis
| ULTI Stock | NOK 2.07 0.02 0.98% |
Ultimovacs ASA is overvalued with Real Value of 1.74 and Hype Value of 2.07. The main objective of Ultimovacs ASA stock analysis is to determine its intrinsic value, which is an estimate of what Ultimovacs ASA is worth, separate from its market price. There are two main types of Ultimovacs ASA's stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Ultimovacs ASA's performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Ultimovacs ASA's stock to identify patterns and trends that may indicate its future price movements.
The Ultimovacs ASA stock is traded in Norway on Oslo Stock Exchange, with the market opening at 09:00:00 and closing at 16:20:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in Norway.
Ultimovacs |
Ultimovacs Stock Analysis Notes
About 48.0% of the company outstanding shares are owned by insiders. The company recorded a loss per share of 5.09. Ultimovacs ASA had not issued any dividends in recent years. Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for various cancers. The company was incorporated in 2011 and is headquartered in Oslo, Norway. ULTIMOVACS ASA is traded on Oslo Stock Exchange in Norway. For more information please call the company at 47 41 38 00 80 or visit https://ultimovacs.com.Ultimovacs ASA Investment Alerts
| Ultimovacs ASA generated a negative expected return over the last 90 days | |
| Ultimovacs ASA has high historical volatility and very poor performance | |
| Ultimovacs ASA has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (164.72 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Ultimovacs ASA has accumulated about 1.85 M in cash with (125.83 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 11.95, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 48.0% of the company outstanding shares are owned by insiders |
Ultimovacs Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 4.11 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Ultimovacs ASA's market, we take the total number of its shares issued and multiply it by Ultimovacs ASA's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Technical Drivers
As of the 27th of November, Ultimovacs ASA has the Variance of 44.34, coefficient of variation of (3,189), and Risk Adjusted Performance of (0.02). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Ultimovacs ASA, as well as the relationship between them. Please validate Ultimovacs ASA mean deviation, standard deviation, information ratio, as well as the relationship between the coefficient of variation and variance to decide if Ultimovacs ASA is priced more or less accurately, providing market reflects its prevalent price of 2.07 per share.Ultimovacs ASA Price Movement Analysis
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Ultimovacs ASA middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Ultimovacs ASA. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Ultimovacs ASA Outstanding Bonds
Ultimovacs ASA issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Ultimovacs ASA uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Ultimovacs bonds can be classified according to their maturity, which is the date when Ultimovacs ASA has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Ultimovacs ASA Predictive Daily Indicators
Ultimovacs ASA intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Ultimovacs ASA stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Ultimovacs ASA Forecast Models
Ultimovacs ASA's time-series forecasting models are one of many Ultimovacs ASA's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Ultimovacs ASA's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Ultimovacs Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Ultimovacs ASA prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Ultimovacs shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Ultimovacs ASA. By using and applying Ultimovacs Stock analysis, traders can create a robust methodology for identifying Ultimovacs entry and exit points for their positions.
Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for various cancers. The company was incorporated in 2011 and is headquartered in Oslo, Norway. ULTIMOVACS ASA is traded on Oslo Stock Exchange in Norway.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Ultimovacs ASA to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Sync Your Broker Now
Sync Your BrokerSync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |
| All Next | Launch Module |
Other Information on Investing in Ultimovacs Stock
Ultimovacs ASA financial ratios help investors to determine whether Ultimovacs Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ultimovacs with respect to the benefits of owning Ultimovacs ASA security.